Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Histamine in immunotherap… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Histamine in immunotherapy of advanced melanoma: a pilot study.

Artikel i vetenskaplig tidskrift
Författare Kristoffer Hellstrand
Peter Naredi
Per Lindnér
Kent Lundholm
Carl-Magnus Rudenstam
Svante Hermodsson
Mats Asztely
Lars-Olof Hafström
Publicerad i Cancer immunology, immunotherapy : CII
Volym 39
Nummer/häfte 6
Sidor 416-9
ISSN 0340-7004
Publiceringsår 1994
Publicerad vid Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi
Institutionen för laboratoriemedicin, Avdelningen för klinisk virologi
Sidor 416-9
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Female, Histamine, therapeutic use, Humans, Interferon-alpha, administration & dosage, Interleukin-2, administration & dosage, Male, Melanoma, therapy, Middle Aged, Pilot Projects
Ämneskategorier Cancer och onkologi

Sammanfattning

Sixteen patients with advanced metastatic malignant melanoma were treated with a high-dose infusion of interleukin-2 (IL-2; 18 x 10(6) IU/m-2 day-1) together with daily subcutaneous (s.c.) injections of interferon alpha (IFN alpha; 3 x 10(6) U/m-2 day-1) in 5-day cycles. Nine of these patients were given histamine (1 mg s.c.) twice daily during treatment with IL-2 and IFN alpha. In the seven patients who did not receive histamine, one partial response (that is a reduction of more than 50% in the total tumour burden) was observed in a patient with skin and lymph node melanoma. In the eight histamine-treated patients evaluable for response, four partial responses were observed. Two other patients showed regression at one site of metastasis but tumours remained unchanged at other sites. Two histamine-treated patients showed complete resolution of extensive liver metastasis. Sites of response in histamine-treated patients also included the subcutis, lymph nodes, skeleton, spleen and muscle. Lung melanoma did not respond to histamine/IL-2/IFN alpha. Three patients with lung tumours responded with significant (more than 50%) reduction of the volume of soft-tissue tumours, suggesting that the response to histamine may be organotropic. Survival was significantly prolonged in patients receiving histamine. Our data suggest that treatment with histamine may improve the antitumour efficacy of immunotherapy in metastatic melanoma.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?